Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regenxbio (RGNX) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to $51.7 million.

  • Regenxbio's Shares Outstanding (Weighted Average) rose 175.0% to $51.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.7 million, marking a year-over-year increase of 175.0%. This contributed to the annual value of $49.5 million for FY2024, which is 1320.48% up from last year.
  • Per Regenxbio's latest filing, its Shares Outstanding (Weighted Average) stood at $51.7 million for Q3 2025, which was up 175.0% from $51.5 million recorded in Q2 2025.
  • Regenxbio's 5-year Shares Outstanding (Weighted Average) high stood at $51.7 million for Q3 2025, and its period low was $41819.0 during Q1 2021.
  • For the 5-year period, Regenxbio's Shares Outstanding (Weighted Average) averaged around $32.2 million, with its median value being $43.5 million (2023).
  • In the last 5 years, Regenxbio's Shares Outstanding (Weighted Average) crashed by 9988.73% in 2021 and then surged by 10150458.72% in 2023.
  • Regenxbio's Shares Outstanding (Weighted Average) (Quarter) stood at $42.4 million in 2021, then rose by 1.68% to $43.2 million in 2022, then grew by 1.35% to $43.7 million in 2023, then rose by 13.2% to $49.5 million in 2024, then grew by 4.4% to $51.7 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $51.7 million for Q3 2025, versus $51.5 million for Q2 2025 and $51.4 million for Q1 2025.